2021
DOI: 10.1080/14656566.2021.1999412
|View full text |Cite|
|
Sign up to set email alerts
|

The evolving atopic dermatitis management landscape

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(7 citation statements)
references
References 68 publications
0
7
0
Order By: Relevance
“…Canine atopic dermatitis diagnosis and treatment remain challenging due to the lack of specialized laboratory tests and medications [9]. Thus, doctors employ varying strategies to treat the condition, such as prescribing corticosteroids, emollients, antihistamines, antibiotics, and immunomodulatory drugs [10].…”
Section: Introductionmentioning
confidence: 99%
“…Canine atopic dermatitis diagnosis and treatment remain challenging due to the lack of specialized laboratory tests and medications [9]. Thus, doctors employ varying strategies to treat the condition, such as prescribing corticosteroids, emollients, antihistamines, antibiotics, and immunomodulatory drugs [10].…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, the safety profile is a key aspect in a chronic disease such as atopic dermatitis [27]. Both traditional and innovative systemic drugs are currently available or under clinical trials (Table 1); however, in many countries only cyclosporine and dupilumab are labelled for atopic dermatitis, while alitretinoin is labelled for chronic hand eczema, including atopic dermatitis of the hand [29].…”
Section: Treatmentmentioning
confidence: 99%
“…Tavecchio et al analysed the dupilumab efficacy on 221 adult atopic dermatitis patients in a reworld study [25]. The patients were stratified into six phenotypes; a consistent improvement was found for all the phenotypes, with the best results in more severe cases (especially erythroderma) [29]. On the other hand, in another Italian real-life study on 165 adult patients treated with dupilumab no statistical differences were reported between seven different atopic dermatitis clinical phenotypes [60].…”
Section: Treatmentmentioning
confidence: 99%
“…Atopic dermatitis (AD) is a chronic-relapsing inflammatory skin condition with variable clinical manifestations, depending on its activity phase [ 105 , 106 ]. AD is characterised by a strict differentiation of CD4 lymphocytes towards the Th2 lineage, thus leading to the increased production of IL-4, IL-5, and IL-13 within the skin.…”
Section: Skin Aquaporins In Inflammatory Dermatological Diseasesmentioning
confidence: 99%